Neurobehavioral Research Inc

1. Boehringer Ingelheim Pharmaceuticals, Inc. $3,477,859 67 payments
2. ITI, Inc. $1,169,470 117 payments
3. Teva Pharmaceuticals USA, Inc. $904,124 111 payments
4. Otsuka Pharmaceutical Development & Commercialization, Inc. $724,076 8 payments
5. Biogen, Inc. $663,293 4 payments
6. Allergan Inc. $631,392 104 payments
7. Janssen Research & Development, LLC $537,254 53 payments
8. Boehringer Ingelheim International GmbH $463,063 259 payments
9. AbbVie, Inc. $436,108 43 payments
10. Hoffmann-La Roche Limited $302,239 13 payments

1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $713,243 82 payments
2. A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) $649,064 3 payments
3. Connex-2 $608,212 30 payments
4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $550,257 4 payments
5. Proof of concept and DRF in BPD $537,195 13 payments
6. PoCC study in patients with PTSD $523,952 7 payments
7. A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder $516,813 30 payments
8. Connex 2 $476,075 5 payments
9. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $453,809 34 payments
10. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) or Major Depressive Disorder $368,557 38 payments

1. Other $49,130 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.